Clinical Trial Update: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with recombinant human endostatin and chemotherapy for unresectable stage III non-small cell lung cancer is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Recombinant human endostatin (recombinant human endostatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hua Zhang | Conditions: Unresectable Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING